Background
==========

Cytomegalovirus (CMV) is a ubiquitous agent that asymptomatically infects the majority of persons \[[@B1],[@B2]\]. Following infection, CMV remains lifelong in a latent state. Therefore, most cases of symptomatic CMV infection are caused by reactivation of a latent virus. CMV infection can occur in immunocompetent individuals, but it most frequently occurs in immunocompromised patients such as recipients of organ transplants, patients undergoing hemodialysis, patients receiving immunosuppressive drugs, and patients with acquired immune deficiency syndrome \[[@B2]\].

The association of CMV infection in severe cases of ulcerative colitis (UC) is well known and the CMV infection in these cases should be treated with an antiviral agent \[[@B3]\]. Advances in diagnostic techniques for CMV infection \[[@B4],[@B5]\] have contributed to our understanding of UC associated with CMV. Domenech *et al.* prospectively studied the prevalence of CMV infection in five groups: active UC requiring intravenous steroids (n=25), steroid-refractory active UC treated with intravenous cyclosporine (n=19), inactive UC on azathioprine (n=25), inactive UC on mesalamine (n=25), and healthy controls (n=25) \[[@B6]\]. Only patients with steroid-refractory active UC (six of 19 patients, 32%) were compromised with CMV infection \[[@B6]\]. Using CMV antigenaemia assay and plasma polymerase chain reaction, it was found that reactivation of CMV up to 8 weeks after treatment with prednisolone and/or immunosuppressants such as cyclosporine was common (52.1%, 25/48) in moderate to severe UC, and CMV disappeared without antiviral therapy \[[@B7]\]. In the above cases, UC was diagnosed first, and CMV infection was identified later.

In 2009, a trigger role of CMV and norovirus was suggested in the development of UC and Crohn's disease, respectively, in experimental murine systems \[[@B8]-[@B10]\]. Here, we report a case in which CMV colitis and UC synchronously developed.

Case presentation
=================

A 50-year-old woman underwent right partial mastectomy for breast cancer in December 2007, after which she was taking anastrozole (Arimidex^R^, AstraZeneca, Osaka, Japan), an aromatase inhibitor, as preventive therapy for breast cancer. There were no other relevant hospitalizations or regular medications. She experienced diarrhea for two days in late November 2009. Then a high fever above 38 centigrade persisted, so she visited the Outpatient Department for feverish patients (day 8). A laboratory test for influenza was negative. The following day, she visited the Division of Breast Surgery, where an antibiotic was prescribed for suspected urinary tract infection. Since the antibiotic was ineffective, she visited the Department of Internal Medicine (day 12). Abdominal ultrasonography revealed thickness of the bowel wall ranging from the transverse to the descending colon. She was referred and admitted to the Division of Gastroenterology (day 14). Laboratory data on admission showed elevated erythrocyte sedimentation rate (65 mm/hr: normal range, \<10 mm/hr), high C-reactive protein (2.3 mg/dl: ≤0.3 mg/dl), elevated α~2~-globulin (11.5%: 4.8-8.6%), mild anemia (hemoglobin 11.5 g/dl: 12.0-15.1 g/dl), mild thrombocytosis (33.0 × 10^4^/mm^3^:15.2-31.4 × 10^4^/mm^3^), and 2% atypical lymphocytes with the normal number of white blood cells (7000/mm^3^: 3900-8800/mm^3^). Although there was no bloody stool, fecal occult blood was over 1000 ng/ml (normal range \<100 ng/ml). Colonoscopy (day 15) showed diffuse inflammation without ulceration in the entire large bowel and pseudomembranes in the sigmoid colon (Figure [1](#F1){ref-type="fig"}A, B). The tentative diagnosis was UC with antibiotic-associated pseudomembranous colitis. Metronidazole 750 mg/day was started. *Clostridium difficile* toxin was negative and stool culture did not reveal any pathogen including enterohemorrhagic *E. coli*, *Campylobactor jejuni*, *Salmonella* species, *Staphylococcus aureus*, and *Krebsiella oxytoca*. Histology of the colon showed crypt abscesses consistent with UC. Therefore, a diagnosis of UC was made and sulfasalazine, 3 g/day, was started (day 22). The fever disappeared in a few days. Her laboratory data improved week by week. Fecal occult blood over 1000 ng/ml lasted until day 40. Fecal occult blood was negative on day 47. Colonoscopy on day 57 confirmed a morphological remission, and she was discharged on the following day.

![Diffuse inflammation in the ascending colon (A) and pseudomembranes in the sigmoid colon (B).](1756-0500-6-40-1){#F1}

Reviewing her hospitalization, it was found that positive CMV antigenaemia (2/150,000 polymorphonuclear neutrophils: normal, no positive cells) tested on day 20 had been missed. Therefore, paraffin embedded colonic biopsy specimens were reevaluated immunohistochemically using a monoclonal antibody against CMV. Although inclusion bodies were not found in hematoxylin and eosin sections, immunohistologically positive cells were found in specimens from the ascending and sigmoid colon (Figure [2](#F2){ref-type="fig"}A, B). Disappearance of CMV antigenaemia and immunohistologically positive cells was ascertained on day 114 and day 125 respectively. She has been in remission to the present (September 2012).

![Positive cells in the ascending (x 400) (A) and sigmoid colon (x 200) (B) stained with monoclonal antibody against cytomegalovirus.](1756-0500-6-40-2){#F2}

Discussion
==========

It is difficult to explain this case as being solely CMV colitis. The most common endoscopic abnormality of CMV colitis is multiple ulcers \[[@B11],[@B12]\]. When whole segments of colon are involved, lesions are skipped in CMV colitis \[[@B13]\]. In this case, ulcers were absent. The lesion was not skipped but continuous and showed crypt abscesses which are consistent with features of ulcerative colitis. In addition, clinical response was obtained with the drug for UC, sulfasalazine. Therefore, the present case can be concluded to be an association of CMV colitis and UC.

Initially this case was thought to be an atypical case of UC in which a high fever instead of bloody stool was manifested and pseudomembrane was observed in the sigmoid colon. Fever is one of the predominant features of CMV infection, and pseudomembrane has been reported in CMV colitis \[[@B14],[@B15]\]. Therefore, these atypical phenomena can be explained by an involvement of CMV infection (colitis).

When UC developed the patient was taking anastrozole, aromatase inhibitor. Since hormone replacement therapy is a protective against relapse in IBD \[[@B16]\], the use of aromatase inhibitor which suppresses the production of estrogen might initiate IBD. However, no UC case associated with anastrozole has been reported to date. There is no UC case among 494 Japanese reports of adverse effects of anastrozole between February 2001, when the drug was started to be used in Japan, and December 2012 (Center of Medical Information, AstraZeneca, Osaka, Japan).

Synchronous onset of CMV colitis and UC was first reported in 1990 \[[@B17]\]. Since then at least fifteen cases have been reported by nine authors (Table [1](#T1){ref-type="table"}) \[[@B18]-[@B25]\]. These cases were primary infections rather than reactivation of CMV. During a retrospective survey of the prevalence of CMV colitis in UC by immunohistochemistry, Kim *et al.* made an intriguing finding: identification of CMV colitis in 8.2% (5/61) of newly diagnosed UC patients \[[@B24]\]. None of the five cases had inclusion bodies on hematoxylin and eosin stain; consequently, none of them was diagnosed with CMV colitis at the time of diagnosis of UC. This means that a majority of synchronous CMV colitis is missed in newly diagnosed UC patients in routine practice. As in Kim *et al*'s case \[[@B24]\], involvement of CMV colitis in the present case had been missed during her hospitalization.

###### 

Synchronous onset of cytomegalovirus colitis and ulcerative colitis

                                            **Age/**     **Chief**     **CMV**   **Atypical**   **Histological**   **Type of UC**
  ---------------------------------------- ---------- --------------- --------- -------------- ------------------ ----------------
  Diepersloot *et al.*, 1990 \[[@B17]\]       39/f     F, HA, AP, BD   primary        \+          IB, IHC, ISH           P
  Lortholary *et al*. 1993 \[[@B18]\]         27/f         F, BD       primary        5%               IB                Lt
  Orvar *et al.*, 1993 \[[@B19]\]             33/f     F, AP, BD, WL   primary       n.d.           IB, IHC              P
  Mate del Tio *et al.*, 1996 \[[@B20]\]      64/m        BD, WL       primary        0             IB, IHC              Lt
  Aoyagi *et al.*, 1998 \[[@B21]\]            41/f         n.d.         n.d.         n.d.           IB, IHC              EC
  Hussein *et al.*, 2006 \[[@B22]\]           29/m       F, AP, WD     primary       43%          IB: negative           EC
  Martin *et al.*, 2006 \[[@B23]\]            28/m     F, AP, HA, BD   primary       18%               IB                Lt
  Kim *et al.*, 2010 \[[@B24]\]               19/m         n.d.         n.d.         n.d.             IHC                Lt
                                              33/m         n.d.         n.d.         n.d.             IHC                EC
                                              43/f         n.d.         n.d.         n.d.             IHC                EC
                                              57/m         n.d.         n.d.         n.d.             IHC                EC
                                              40/f         n.d.         n.d.         n.d.             IHC                Lt
  Kim *et al.*, 2012 \[[@B25]\]               58/m         n.d.         n.d.         n.d.             IHC                EC
                                              39/m         n.d.         n.d.         n.d.             IHC                Lt
                                              68/m         n.d.         n.d.         n.d.           IB, IHC              Lt
  Present case                                50/f           F         primary        2%              IHC                EC

UC, ulcerative colitis; CMV, cytomegalovirus; f, female; m, male; F, fever; HA, headache; AP, abdominal pain.

BD, bloody diarrhea; WL, weight loss; WD, watery diarrhea; n.d., not described; IB, inclusion body.

IHC, immunohistochemistry; ISH, in situ hybridization; P, proctosigmoiditis; Lt, left-sided colitis, EC, entire colitis.

De novo inflammatory bowel disease is an increasingly recognized entity: de novo inflammatory bowel disease, a more common UC than Crohn's disease, develops after solid organ transplantation \[[@B26]\]. The incidence of de novo IBD in the transplanted patients is estimated to be ten times the expected incidence of IBD in the general population \[[@B27]\]. The main risk factor of de novo IBD has been found to be CMV infection \[[@B27]-[@B30]\]. Onyeagocha *et al*. investigated the significance of CMV infection on the development of colitis in a murine system \[[@B8]\]. Murine CMV (MCMV) infection resulted in lasting elevation of antibodies to gut commensal bacteria that is observed in human IBD \[[@B10]\]. Colitis developed following a trigger (dextran sodium sulfate) in a far more severe form in MCMV-infected mice than in mice treated by the trigger alone. They concluded that (latent) CMV infection may predispose to developing IBD.

Conclusion
==========

We have reported a case in which CMV colitis and UC synchronously developed. It is plausible that a subset (a few to several per cent) of UC patients develop synchronous CMV infection. Further studies are needed to elucidate the plausibility.
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